We are today happy to announce that The Norwegian Research Council has approved Hubro Bioscience’s SkatteFUNN application. The approval secures annual refunding of 19% of the company’s R&D expenses over the three-year period 2025-2027. The estimated refund for the ongoing development of the company’s diagnostic tests is up to a total of 2.3 mill NOK (approx. 200 kEURO).
